麻豆视频

Global Breast Cancer Screening Tests Market Trends and Insights

Rising Prevalence of Breast Cancer

Global incidence climbed to 2.3 million cases in 2024 and is projected to reach 2.9 million by 2030, a trajectory driven by aging demographics, urban lifestyle shifts, and broader diagnostic reach.^{[1]World Health Organization, 鈥淏reast Cancer Screening Guidelines and Programs,鈥� who.int} The United States logged 310,000 new diagnoses in 2025, while China reported 420,000, underscoring the dual pressure of scale and urbanization. Disease onset before 50 now accounts for 12% of Western cases, prompting guideline bodies to lower the screening start age from 50 to 40 years. This policy change alone expands the breast cancer screening tests market by an estimated 25 million women. Mortality is falling by 1.3% annually in high-income regions thanks to earlier detection, yet stagnates in low-resource countries, where coverage remains below 20%, highlighting the opportunity for mobile and point-of-care modalities.

Favorable Government Screening Recommendations

The 2024 U.S. shift to age-40 biennial mammography lowers mortality 19% in women 40-49, pushing volume through the reimbursement pipeline. The U.K. added women 47-73, funding GBP 120 million for mobile vans and training. Japan mandated annual ultrasound for dense breast tissue, affecting 40% of its cohort, and swelling equipment demand. China is subsidizing 70% of rural exam costs for 50 million women, pairing subsidies with AI triage in county hospitals. Compliance frameworks such as the FDA鈥檚 MQSA align volume with strict quality metrics.

Technological Advances In 3-D Mammography

Digital Breast Tomosynthesis adoption reached 68% of U.S. facilities in 2025 after reimbursement parity eliminated the price gap with 2-D units.^{[2]Radiological Society of North America, 鈥淒igital Breast Tomosynthesis: Clinical Outcomes and Adoption Trends,鈥� rsna.org} Systems that synthesize 2-D views from raw DBT data cut exam time by a third and raise detection by 1-2 cancers per 1,000 screens. Photon-counting detectors reduce radiation 30% while preserving resolution, easing patient concerns. The upshot: sites report 10-12% higher satisfaction scores and 8% fewer malpractice claims, reinforcing the need for refresh cycles.

Intensifying Public-Private Awareness Campaigns

Retail-clinic coalitions delivered 120,000 free mammograms to underserved U.S. women in 2024, finding 480 early cancers.^{[3]American Cancer Society, 鈥淪creen to Save Initiative,鈥� cancer.org} In 2025, India鈥檚 200 mobile vans screened 300,000 women, 70% of whom were at stages I-II. Brazil鈥檚 Pink October lifted national uptake by 18% with BRL 150 million in corporate sponsorships. Programs that merge education with on-site access convert intent into exams at three times the rate of message-only drives, guiding future outreach design.

Radiation-Exposure Concerns Among Patients

Modern mammography delivers 0.4 milligrays per view, yet 22-28% of surveyed women still cite radiation fear, often conflating CT doses with screening levels. Density notifications, while clinically useful, inadvertently raise anxiety and push some women toward costlier MRI. Vendor countermeasures include photon-counting detectors and contrast-enhanced techniques that can reduce dose by up to 40%.

High Cost of Advanced Imaging Equipment

Premium DBT plus AI can cost USD 500,000 upfront and another USD 60,000 per year in service, far beyond the means of systems operating on USD 200 per capita budgets. Africa has fewer than 200 functional mammography units across 48 countries. Pay-per-scan leasing at USD 15 an exam and certified refurbished units at 50-60% discounts are easing barriers, but cannot close the gap alone.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Screening Modality: Blood-Based Biomarkers Gain Momentum

Imaging-based Tests retained 66.02% of the revenue in 2025, yet the breast cancer screening tests market for Blood-based Biomarker Tests is expanding the fastest at a 9.06% CAGR through 2031. Mammography generated 1.2 billion exams, with Digital Breast Tomosynthesis overtaking 2-D in the United States and nearing parity in Europe. Handheld ultrasound devices added 15 million Asia-Pacific screens, while fast MRI protocols halved scan time and reduced costs to USD 600, pushing the modality beyond high-risk cohorts. Guardant鈥檚 Shield and Exact Sciences鈥� CancerSEEK multi-cancer assays, priced around USD 995, now compete with MRI for high-risk women, securing payer pilots that could widen use once mortality endpoints mature. Multi-analyte panels integrating proteins, microRNAs, and ctDNA are lining up behind early adopters, though regulatory clarity will ultimately dictate uptake.

By End User: Specialty Centers Capture High-Acuity Volume

Hospitals contributed 46.27% of 2025 sales, but Specialty Cancer Centers are pacing 11.63% CAGR, outstripping hospital growth. The breast cancer screening tests market for networked diagnostics centers is growing as Radiology Partners and others consolidate 45 U.S. clinics, leveraging common AI platforms to increase throughput. Retail chains performed 8 million mammograms at cash prices of USD 99-149, reaching uninsured patients. Specialty centers differentiate by integrating imaging, liquid biopsy, and polygenic risk into a single visit; Memorial Sloan Kettering鈥檚 program cut overdiagnosis by 22% and missed cancers 8% in a 50,000-person cohort. Bundled payments of USD 8,000 per screening-to-treatment episode, versus USD 12,000 under fee-for-service, cement their value-based edge.

Geography Analysis

North America generated 41.08% revenue in 2025, backed by Medicare鈥檚 USD 150-200 reimbursement per exam and a 2024 guideline shift that added 20 million eligible women. Three large states require dense-breast ultrasound coverage without cost-sharing, pushing supplemental volume. Canada invested CAD 180 million (USD 133 million) in DBT upgrades, boosting penetration from 22% to 38% in one year. Mexico鈥檚 mobile-unit rollout achieved 50% higher early-detection rates than fixed-site screening. Persistent radiologist shortages of 2,000 by 2028 are keeping AI triage and cross-border teleradiology in demand.

Asia-Pacific is the fastest-growing region, with a 10.27% CAGR to 2031. China鈥檚 Healthy China 2030 allocates CNY 50 billion (USD 7 billion) for screening expansion to 70% urban coverage. India鈥檚 Ayushman Bharat added screening at 5,000 health centers, targeting 30 million women by 202. Japan, already at 50% participation, deploys combined mammography-ultrasound for dense tissue, while South Korea鈥檚 program pilots AI in 200 municipal clinics. Radiologist density varies sharply from 0.8 per 100,000 in India to 8 in Japan, necessitating task shifting and cloud AI solutions.

Centralized invitation systems and free-of-charge protocols keep participation near 75%. Germany now reimburses MRI for women with 鈮�20% lifetime risk, lifting MRI screens by 18%. The U.K. cleared a COVID backlog after AI cut read times by a quarter. France鈥檚 dense-breast notification pilot raised diagnostic yield by 12% but also false positives by 8%, prompting protocol review. Spain began integrating liquid biopsy for BRCA carriers, detecting 15% more interval cancers. Elsewhere, donor-funded mobile programs seed infrastructure in Nigeria, Kenya, South Africa, Brazil, and Argentina, but still face out-of-pocket hurdles for 40-50% of target populations.

Regulatory Landscape

In the United States, mammography providers operate under the FDA-administered Mammography Quality Standards Act (MQSA), with updated requirements from the 2023 MQSA Final Rule required for facility compliance since September 10, 2024. This tighter quality framework directly ties screening volume to inspection, documentation, and patient communication obligations (including breast density notification). Device makers route new mammography systems, CAD, and AI-enabled screening software through FDA pathways such as 510(k), De Novo, or PMA, depending on risk profile and predicate availability.

In Europe, manufacturers and laboratories must align with the EU In Vitro Diagnostic Regulation (IVDR, Regulation (EU) 2017/746), where screening-related cancer assays fall under defined classification rules (including Rule 3h). Regulation (EU) 2024/1860 (adopted June 2024) adjusted implementation mechanics by extending certain transitional provisions and setting a staged approach for Eudamed rollout, aimed at reducing the risk of supply disruptions around the May 2025 compliance transition window. Interoperability and documentation expectations for imaging and CAD outputs are reinforced by standards such as DICOM (including mammography image modules and mammography CAD structured reporting templates), which support cross-site data exchange and multi-vendor workflow integration.

Market Opportunities and Future Outlook

A near-term whitespace is operational throughput and standardization at the point of care. AI being cleared and incorporated into routine mammography workflows can offset radiologist constraints and improve consistency across high-volume screening networks. FDA clearances and authorizations in 2026 (including Lunit's 3D mammography AI update and DeepHealth enhancements that integrate prior exams and add breast arterial calcification assessment) create concrete building blocks for providers seeking to unify image acquisition, triage, and longitudinal comparison across fleets, particularly as eligibility expands down to age 40. For vendors, this is shifting competition toward integrated platforms that can be upgraded via software while staying aligned with MQSA requirements at the facility level.

Modality expansion beyond standard mammography into MRI and tissue-assessment adjacencies can also widen the clinical episodes linked to screening programs. In July 2026, Quibim launched QP-Breast with CE and UKCA marking for MRI-based breast cancer detection, providing an additional option for sites using MRI in dense-breast and high-risk pathways. Regulatory momentum for AI integration is also reflected in policy discussion, including the April 2026 introduction of H.R. 8526 in the U.S. House of Representatives, which proposes updates to mammography facility quality standards around AI system integration and could accelerate adoption where compliance language and auditability are prerequisites for enterprise procurement.